Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

AXA Framlington Biotech Class Z - Accumulation (GBP)

Sell:333.40p Buy:333.40p Change: 2.50p (0.76%)
Prices as at 12 December 2018
Sell:333.40p
Buy:333.40p
Change: 2.50p (0.76%)
You can buy or sell holdings in this fund through an ISA, Lifetime ISA, SIPP or Fund & Share Account
Prices as at 12 December 2018
Sell:333.40p
Buy:333.40p
Change: 2.50p (0.76%)
Prices as at 12 December 2018
You can buy or sell holdings in this fund through an ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Also available as income units Help

Charges and Savings

Initial charges
Initial charge: 0.00%
Initial saving from HL: 0.00%
HL dealing charge: Free
Net initial charge: 0.00%
Annual charges
Performance fee: No  
Ongoing charge (OCF/TER): 0.82%
Ongoing saving from HL: 0.00%
Net ongoing charge: 0.82%
There are other unit types of this fund available:
Inclusive - Class R - Income (GBP) (Net ongoing charge 0.82%)
Inclusive - Class R - Accumulation (GBP) (Net ongoing charge 0.82%)
Class Z - Income (GBP) (Net ongoing charge 0.82%)

In some cases the ongoing savings are provided by our loyalty bonus. Loyalty bonuses are tax-free in an ISA or SIPP. However, they may be subject to tax in a Fund & Share Account which would, in effect, reduce their value and increase the net ongoing charge.


Other Information

Unit type: Unbundled
Manager:
Linden Thomson
Fund launch date: 26 November 2001
Sector: Specialist
Fund size: £469 million
Number of holdings: 65
Fund type: Unit Trust
Accumulation/income: Accumulation
Dealing frequency: Daily
Valuation point: 12:00
Trustee: The National Westminster Bank plc
Minimum investment: £100.00
Charges deducted from: Income
Available in a regular savings plan: Yes
Minimum regular savings value: £25.00

Performance

12/12/13 to 12/12/14 12/12/14 to 12/12/15 12/12/15 to 12/12/16 12/12/16 to 12/12/17 12/12/17 to 12/12/18
Annual return 49.54% 6.91% -2.51% 9.48% 6.54%

Please remember past performance is not a guide to future returns. Where no data is shown, figures are not available. This information is provided to help you choose your own investments, remember they can fall as well as rise in value so you may not get back the original amount invested.

View fund chart

Our view on this fund

The Wealth 150 is the list of what we believe are the best funds in each sector. If a fund is not within our Wealth 150 this is not necessarily a recommendation to sell. However, if you are thinking of adding to your investments we believe Wealth 150 funds are superior alternatives. View funds on the Wealth 150 »

Our latest article

The AXA Framlington Biotech Fund aims to make the most of the opportunities on offer in one of the most interesting and exciting areas of the stock market. We review the fund's performance and share our view on its prospects.

Fund Objective

To provide long term capital appreciation by investing principally in equity securities of companies in the biotechnology, genomics and medical research industries worldwide.

Income Details

Income paid: Bi-annually
Type of payment: Dividend
Ex-dividend date: 1 March 2019 1 September 2019
Payment date: 30 April 20194 31 October 20194

This data is provided by Funds Library. HL accepts no responsibility for its accuracy and you should independently check data before making any investment decision. All yields are variable and not guaranteed. There is currently no yield information available for this fund.

Sector Weight
Pharmaceuticals & Biotechnology 95.68%
Cash and Equiv. 2.88%
Non-Classified 1.44%
Country Weight
United States 83.01%
Ireland 3.44%
Cash and Equiv. 2.88%
United Kingdom 2.32%
France 2.25%
Belgium 2.21%
Netherlands 1.22%
Switzerland 0.96%
Germany 0.72%
Sweden 0.55%

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Prices provided by Morningstar, correct as at 12 December 2018. Data provided by Funds Library, correct as at 31 October 2018.

FundsLibrary
You can buy or sell holdings in this fund through an ISA, Lifetime ISA, SIPP or Fund & Share Account

4 If you elect to receive the income from a Vantage ISA or Vantage Fund & Share Account, we will collect any dividends for you and then pay them directly into your bank account within the first 10 working days of the following month.